Moreover, this failure to inhibit NF-κB by Cbl during inflammation, with positive outcomes, has now also been observed by a group who were aware of our findings [57] and, independently, in a Cbl cancer model by Marguerite et al. (2012, Marc Marten personal communication to Wheatley). The gene discussed is NFKB1; the disease is cancer.